SCHEMBL5481833

SCHEMBL5481833

O=C1Nc2ccccc2C1=Cc1ccccc1Cl

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 2/20 0.68
PLK4 O00444 2/20 0.68
PLK1 P53350 2/20 0.68
FLT3 P36888 6/20 0.61
MAP3K7 O43318 1/20 0.58
TAB1 Q15750 1/20 0.58
RET P07949 4/20 0.57
PDGFRB P09619 4/20 0.57
KDR P35968 4/20 0.57
NTRK1 P04629 3/20 0.57
DAPK3 O43293 2/20 0.57
PRKD3 O94806 2/20 0.57
MAP4K4 O95819 2/20 0.57
LCK P06239 2/20 0.57
FYN P06241 2/20 0.57
CSF1R P07333 2/20 0.57
LTK P29376 2/20 0.57
MAPK8 P45983 2/20 0.57
CSNK1A1 P48729 2/20 0.57
CDK7 P50613 2/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5481832 1.00 NPC1 (0.68) NPC1PLK4PLK1FLT3MAP3K7
SCHEMBL5472209 0.85 FLT3 (0.59) NPC1PLK4PLK1FLT3MAP3K7
SCHEMBL5472619 0.85 LRRK2 (0.58) NPC1PLK4PLK1FLT3MAP3K7
SCHEMBL14448885 0.85 LRRK2 (0.58) NPC1PLK4PLK1FLT3MAP3K7
SCHEMBL14448904 0.85 FLT3 (0.59) NPC1PLK4PLK1FLT3MAP3K7
SCHEMBL5472208 0.85 FLT3 (0.59) NPC1PLK4PLK1FLT3MAP3K7
SCHEMBL5469641 0.85 LRRK2 (0.70) RETPDGFRBRPS6KA3LRRK2
SCHEMBL5472614 0.85 LRRK2 (0.58) NPC1PLK4PLK1FLT3MAP3K7
SCHEMBL5469637 0.85 LRRK2 (0.70) RETPDGFRBRPS6KA3LRRK2
SCHEMBL5470660 0.84 CDK7 (0.62) NPC1PLK4PLK1FLT3RET

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070167488-A1 Novel therapeutic use LEO PHARMA A/S (DK) 2007-07-19 US claimed
EP-1696906-A1 NOVEL THERAPEUTIC USE OF INDOLINONE DERIVATIVES Leo Pharma A/S (DK) 2006-09-06 EP claimed
WO-2005058309-A1 NOVEL THERAPEUTIC USE OF INDOLINONE DERIVATIVES LEO PHARMA A/S (DK) 2005-06-30 WO claimed
US-20070167488-A1 Novel therapeutic use LEO PHARMA A/S (DK) 2007-07-19 US disclosed
EP-1696906-A1 NOVEL THERAPEUTIC USE OF INDOLINONE DERIVATIVES Leo Pharma A/S (DK) 2006-09-06 EP disclosed
WO-2005058309-A1 NOVEL THERAPEUTIC USE OF INDOLINONE DERIVATIVES LEO PHARMA A/S (DK) 2005-06-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070167488-A1 Novel therapeutic use MAG, PMP22, MYT1 NPC1 4188/4885PLK4 3502/4885PLK1 1202/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.